Quinacrine downregulates SLC3A2 transcripts by disrupting the SSRP1‐JUNB interaction, thereby offering a promising therapeutic approach for PTCL. The gene discussed is SSRP1; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.